Radioimmunotherapy with alpha-emitting nuclides

This review discusses the application of alpha particle-emitting radionuclides in targeted radioimmunotherapy. It will outline the production and chemistry of astatine-211, bismuth-212, lead-212, actinium-225, bismuth-213, fermium-255, radium-223 and terbium-149, which at present are the most promis...

Full description

Saved in:
Bibliographic Details
Published in:European journal of nuclear medicine 1998-09, Vol.25 (9), p.1341-1351
Main Authors: MCDEVITT, M. R, SGOUROS, G, FINN, R. D, HUMM, J. L, JURCIC, J. G, LARSON, S. M, SCHEINBERG, D. A
Format: Article
Language:English
Subjects:
Alpha Particles - therapeutic use
Animals
Biological and medical sciences
Contrast media. Radiopharmaceuticals
Humans
Medical sciences
Miscellaneous
Pharmacology. Drug treatments
Radioimmunotherapy
Radioisotopes - therapeutic use
Radiotherapy Dosage
Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This review discusses the application of alpha particle-emitting radionuclides in targeted radioimmunotherapy. It will outline the production and chemistry of astatine-211, bismuth-212, lead-212, actinium-225, bismuth-213, fermium-255, radium-223 and terbium-149, which at present are the most promising alpha-emitting isotopes available for human clinical use. The selective cytotoxicity offered by alpha particle-emitting radioimmunoconstructs is due to the high linear energy transfer and short particle path length of these radionuclides. Based upon the pharmacokinetics of alpha particle-emitting radioimmunoconstructs, both stochastic and conventional dosimetric methodology is discussed, as is the preclinical and initial clinical use of these radionuclides conjugated to monoclonal antibodies for the treatment of human neoplasia.
ISSN:0340-6997
1619-7070
1619-7089
DOI:10.1007/s002590050306